Compare the outcomes of dinutuximab given early with Induction therapy to the effects of standard Induction therapy with the addition of dinutuximab later in therapy in people with high-risk neuroblastoma (HRNBL) to find out which is better.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Thomas Alexander
Pediatrics - Hematology/Oncology
Clinical or Medical
Interventional
Cancer (Pediatric Cancers)
24-2426
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
